Search clinical trials for: Gardasil-9

Total 982 results

Laval University
Centers for Disease Control and Prevention

Completed

Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9

Human Papillomavirus Vaccines

Canada
Western Institute for Veterans Research
Merck Sharp & Dohme LLC; University of Utah

Recruiting

Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts

Warts

United States
London School of Hygiene and Tropical Medicine
Merck Sharp & Dohme LLC; Public Health England; University of Cambridge

Active, not recruiting

HPV Vaccination in Africa- New Delivery Schedules Alias The HANDS HPV Vaccine Trial (HPV)

Human Papillomavirus Vaccine

Gambia
Boston Medical Center
Merck Sharp & Dohme LLC

Recruiting

An Exploratory Open-Label Clinical Trial Evaluating the Immunogenicity of the 9-valent 2-dose HPV Vaccination Regimen

HPV Infection

United States
Shanghai Zerun Biotechnology Co.,Ltd
Walvax Biotechnology Co., Ltd.

Active, not recruiting

Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9

Cervical Cancer | Papillomavirus Infections | CIN | Genital Wart | VIN

China
Centre Hospitalier Universitaire de la Réunion

Completed

Study of the Impact of a School Program Combining - Promotion of HPV Vaccination and HPV Vaccine Offer in Middle School - on Adherence to HPV Vaccination in Middle School Students (PROM SSCOL)

Papilloma Viral Infection

France
Boston Medical Center
Merck Sharp & Dohme LLC

Recruiting

Immunogenicity of the 9vHPV Vaccination 2-dose Regimen Among Children 4 to 8 Years Old, An Exploratory Immunogenicity Study

Human Papilloma Virus

United States
Eastern Virginia Medical School
Merck Sharp & Dohme LLC

Recruiting

Occupational Exposure to Human Papilloma Virus (HPV) and Prophylactic Vaccination

Papillomavirus Vaccines

United States
University Health Network, Toronto
Merck Sharp & Dohme LLC

Not yet recruiting

HPV-SAVE_Merck_Sub-Study for Preventing Recurrence of HSIL

Anal Cancer | Human Papilloma Virus | Anal Intraepithelial Neoplasia

Canada
National Institute of Allergy and Infectious Diseases...

Recruiting

Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in People With Idiopathic CD4 T Cell Lymphocytopenia

Idiopathic CD4 T Cell Lymphocytopenia

United States
Milton S. Hershey Medical Center

Withdrawn

HPV Vaccine in Postpartum Women

HPV Infection
Louisiana State University Health Sciences Center...
Merck Sharp & Dohme LLC

Recruiting

Immunogenicity of Gardasil-9 HPV Vaccine in People Living With HIV (AGO-Gard)

Cervical Intraepithelial Neoplasia | Human Immunodeficiency Virus | Anal Intraepithelial Neoplasia | Papillomavirus Infection | Papillomavirus Vaccines | Serology | Oral Cavity Infection

United States
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Safety of the 9-valent Human Papillomavirus (9vHPV) Vaccine in Japanese Boys and Girls (V503-066)

Papillomavirus Infections

Japan
Medical College of Wisconsin
Merck Sharp & Dohme LLC

Recruiting

Immunogenicity of HPV Vaccine in Transplant Recipients.

Chronic Kidney Diseases | Kidney Transplant

United States
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

Uterine Cervical Neoplasms | Papillomavirus Infections | Vulvar Neoplasms | Vaginal Neoplasms | Condylomata Acuminata | Adenocarcinoma in Situ

Vietnam
Laval University

Completed

Immunogenicity and Safety of Gardasil-9 and Cervarix

HPV Vaccines Immunogenicity and Safety

Canada
Merck Sharp & Dohme LLC

Active, not recruiting

Immunogenicity and Safety of V503 in Chinese Males 9 Through 19 Years Old (V503-053)

Genital Warts

China
Miquel Angel Pavon Ribas
Catalan Institute of Health; Hospital del Mar

Recruiting

A Study to Assess the Reduction of Human Papillomavirus (HPV) Viral Infectivity and Transmission in HPV-Positive Women After Vaccination With 9vHPV (RIFT-HPV) (RIFT-HPV)

Cervical Intraepithelial Neoplasia Grade I/ II/ III (CIN I/II/III) | Human Papillomavirus (HPV) Infections | High-risk HPV | HPV-16/ 18

Spain
Massachusetts General Hospital
Bill and Melinda Gates Foundation; Kenya Medical Research Institute

Active, not recruiting

The KEN SHE Study on HPV-vaccine Efficacy

Papillomavirus Infections

Kenya
Imperial College London

Not yet recruiting

Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative The NOVEL Trial (NOVEL)

Neoplasia
Massachusetts General Hospital
National Cancer Institute (NCI); Fred Hutchinson Cancer Center; University of... and other collaborators

Not yet recruiting

Efficacy of Human Papillomavirus (HPV) Vaccination to Prevent Infection Among Women Living With HIV. (HOPE II)

Hiv | Human Papilloma Virus
Universitaire Ziekenhuizen KU Leuven

Completed

Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients

Hiv | Human Papilloma Virus | Organ Transplants

Belgium
Erasmus Medical Center
Dutch Cancer Society

Not yet recruiting

Adjuvant Nonavalent HPV Vaccination in Women Treated for Vulvar HSIL (VulVaccin)

HPV | Vulvar HSIL

Netherlands
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064)

Warts, Genital | Neoplasms, Anal

Japan
Merck Sharp & Dohme LLC

Active, not recruiting

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

Papillomavirus Infections

United States, Belgium, Brazil, Colombia, Czechia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Spain, Taiwan, Thailand
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Not yet recruiting

Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women

Cervical Cancer | Condylomata Acuminata

China
University of British Columbia
Merck Canada Inc.

Completed

Long Term Immune Memory Responses to HPV Vaccination Following 2 vs 3 Doses of Quad-HPV Vaccine (Merck08)

Human Papillomavirus

Canada
Xiamen University
Xiamen Innovax Biotech Co., Ltd; Beijing Wantai Biological Pharmacy Enterprise...

Completed

Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age

Cervical Cancer | Condylomata Acuminata

China
Columbia University
Merck Sharp & Dohme LLC; Jhpiego

Active, not recruiting

HPV Vaccination in HIV Infected and HIV Uninfected Adolescents in Eswatini

Hiv | HPV Infection | HPV Vaccine

Swaziland
Eastern Virginia Medical School
Merck Sharp & Dohme LLC

Unknown

A Model for Implementation of Cervical Cancer Screening and HPV Vaccination the Emergency Department: a Pilot Study

Genital Human Papilloma Virus Infection

United States
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd.

Completed

Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS | HPV Infections

China
Sinocelltech Ltd.

Recruiting

A Phase II Study of SCT1000 in Healthy Women Aged 18 to 45 Years

Randomized | Prevention | Interventional

China
National Vaccine and Serum Institute, China
Guangxi Center for Disease Control and Prevention; Simoon Record Pharma Information... and other collaborators

Completed

Immunogenicity AND Safety Study of the 11 Valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha)

HPV Infection | HPV-Related Cervical Carcinoma

China
GlaxoSmithKline

Active, not recruiting

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

Cervical Intraepithelial Neoplasia

United States
University of Alabama at Birmingham
Merck Investigator Studies Program

Not yet recruiting

Developing and Evaluating a Novel Approach to Improve HPV Vaccination Coverage Among High-risk, Under-immunized Adults Via the Emergency Department

Human Papilloma Virus

United States
Merck Sharp & Dohme LLC

Completed

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Papillomavirus Infections | Coronavirus Disease (COVID-19)

United States
Shanghai Bovax Biotechnology Co., Ltd.

Recruiting

Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS

China
Shanghai Bovax Biotechnology Co., Ltd.
Chongqing Bovax Biopharmaceutical Co., Ltd.

Completed

Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | CIN1 | CIN2 | CIN3 | VaIN1 | VaIN2 | VaIN3 | Genital Wart | VIN 1 | VIN 2 | VIN 3 | AIS

China
McGill University

Active, not recruiting

Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study (TRAP-HPV)

Human Papillomavirus Infection

Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Gardasil 9 Vaccine in Preventing HPV Infection in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant

Hematopoietic and Lymphoid Cell Neoplasm | Allogeneic Hematopoietic Stem Cell Transplant Recipient

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); Evandro Chagas National Institute of Infectious... and other collaborators

Active, not recruiting

Establishing Optimal Number of Doses for HPV Vaccination in Children and Adolescents Living With HIV, OPTIMO Trial (OPTIMO)

HIV Infection

Peru, Brazil, Haiti
Sinocelltech Ltd.

Recruiting

A Phase I Safty and Immunogenicity Study of SCT1000 in Healthy Women Aged 18 to 45 Years

HPV Infection Vaccine Safety SCT1000

China
Kenya Medical Research Institute
Merck Sharp & Dohme LLC; University of Washington

Completed

A Cohort Study to Assess Sustained Immunogenicity to qHPV Vaccine Among HIV-infected Girls and Boys Age 9-14 Years

HIV-1 Infection | Human Papillomavirus
Merck Sharp & Dohme LLC

Completed

Immunogenicity and Tolerability of Broad Spectrum Human Papillomavirus (HPV) Vaccine in Adult and Young Adult Women (V503-004)

Cervical Cancer | Vulvar Cancer | Vaginal Cancer | Human Papillomavirus Infection | Genital Warts

Austria, Belgium, Finland, Germany, Italy, Spain
Beijing Health Guard Biotechnology, Inc
National Institutes for Food and Drug Control, China; Yunnan Center for Disease... and other collaborators

Active, not recruiting

A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China

Human Papillomavirus Infection

China
Preventive Oncology International, Inc.
Merck Sharp & Dohme LLC; Peru Instituto Nacional de Enfermadades Neoplasticas...

Completed

The Development of a "Mother/Child, Screen, Treat and Vaccinate Program" in Manchay and Iquitos, Peru (PERCAPS)

Cervical Cancer | Cervical Intraepithelial Neoplasia | Human Papillomavirus | Cervical Dysplasia | Cervical Neoplasm

Peru
Cumberland Pharmaceuticals

Completed

Phase 2 Trial of TD-6424 (Telavancin) Versus Standard Therapy for Complicated Gram Positive Skin and Skin Structure Infections (Gram Positive cSSSI) (FAST2)

Infections, Gram-positive Bacterial

United States
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Vaccines | Meningococcal Vaccines

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Completed

Preparedness Study - HPV Vaccine

Sexual Transmission of Infection

United States, South Africa
AIDS Malignancy Consortium
National Cancer Institute (NCI); University of California, Los Angeles; Merck... and other collaborators

Active, not recruiting

HPV Vaccine Therapy in Reducing High-Grade Cervical Lesions in Patients With HIV and HPV (COVENANT)

HIV Infection | AIDS-Related Human Papillomavirus Infection | High Grade Cervical Squamous Intraepithelial Neoplasia

Uganda, Kenya, Zimbabwe, South Africa, Malawi

Search clinical trials for: Gardasil-9

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Georgia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations